Compound I Salts Enhance STING Pathway Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compounds for cancer treatment, specifically targeting STING signaling, face challenges in bioavailability and stability, which affect their efficacy as drug substances.
Innovation Solution
Development of salts and crystals of Compound (I), such as di-ammonium and mono-ammonium salts, which exhibit specific diffraction peaks in powder X-ray diffraction, enhancing their potential as pharmaceutical agents by improving hygroscopicity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Compound (I) is used as a pharmaceutical compound for cancer treatment, then it can activate the STING pathway and show antitumor activity, but its bioavailability and stability are insufficient
Solution Approach 1:
The patent applies parameter changes by converting Compound (I) into different salt forms (ammonium salt, sodium salt, potassium salt) to modify its physical and chemical properties. This transformation changes the solubility, stability, and bioavailability parameters of the compound without altering its core STING pathway activation capability, thereby resolving the contradiction between stability and bioavailability
Solution Approach 2:
The patent creates composite material systems by forming salts of Compound (I) with various counterions (ammonium, sodium, potassium). These composite salt forms combine the active pharmacological compound with stabilizing counterions, improving overall stability while maintaining or enhancing bioavailability compared to the free acid form
2Reliability
If salts of Compound (I) are developed to improve bioavailability and stability, then their potential as pharmaceutical agents is enhanced, but the complexity of salt selection and characterization increases
Solution Approach 1:
The patent applies local quality by selecting specific counterions (ammonium, sodium, potassium) that provide localized improvements in desired properties. Each salt form is optimized for specific characteristics - ammonium salt for enhanced solubility, sodium/potassium salts for improved stability - allowing selection based on specific pharmaceutical needs without overwhelming complexity
Solution Approach 2:
The patent uses common inorganic bases (ammonia, sodium hydroxide, potassium hydroxide) as intermediaries to convert Compound (I) into stable salt forms. These intermediary substances facilitate the salt formation process and provide a systematic approach to generating pharmaceutically acceptable salts, reducing the complexity of salt selection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The salts and crystals of Compound (I) demonstrate enhanced bioavailability and stability, potentially leading to effective activation of the STING pathway and potent antitumor activities, making them suitable for treating various cancers like glioma, melanoma, and colon cancer.
Implementation Method 1
which exhibit specific diffraction peaks in powder X-ray diffraction
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34λ5,39λ5-diphosphaoctacyclo[28.6.4.13,36.128,31.04,8.07,12.019,24.023,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals.